Donor Dopamine and Initial Graft Function

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Donor pre-treatment with dopamine reduces injury to the kidney graft with consequences on the clinical performance immediately after transplantation: Donor dopamine reduces the requirement of dialysis post transplant, and results in renal function improvements.

The purpose of the study is to investigate the potentially therapeutic impact of donor preconditioning with low dose dopamine in human renal transplant recipients from a brain dead donor.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitätsmedizin Mannheim
• Collaborators: Eurotransplant International Foundation, Leiden, The Netherlands; Novartis; Regional Organ Procurement Organization (DSO), Baden-Wuerttemberg, Germany; Regional Organ Procurement Organization (DSO), Bavaria, Germany
• Treatments: Dopamine; Dopamine Agents

Criteria

Inclusion Criteria:

Donors:

• Brain death confirmed

• Given consent to organ donation

• Current s-creatinine < 2mg/dl

• On admission s-creatinine < 1.3mg/dl

Recipients:

• Age over 18 years

• Placed on the waiting list

• Organ allocation according to ET standards

Exclusion Criteria:

Donors:

• Application of dopamine/dobutamine/adrenaline

• Application of noradrenaline > 0.4µg/kg*min

• Hemodynamic instability

Recipients:

• Refusal to participate in study /data analysis

• Pregnancy